Kornimate/medical-research-clean huggingface dataset:
different anesthesia methods on development of postnatal depression after cesarean delivery

Conditions: Pregnancy Related

Summary: childbirth is one of the most painful experiences for a woman. labor and period of pregnancy is associated with an increased risk of psychiatric disorders for a woman. the demands of pregnancy and childbirth make patients vulnerable to psychiatric disorders such as postpartum depression (ppd), anxiety, and stress disorders. women with postpartum psychiatric disorders have high mortality rates. the most common postpartum psychiatric disorder is ppd. ppd occurs any time in pregnancy or in the first four weeks after delivery. it may lead to complications such as emotional lability in the mother. this situation may also effect the child.

childbirth is one of the most painful experiences for a woman. labor and period of pregnancy is associated with an increased risk of psychiatric disorders for a woman. the demands of pregnancy and childbirth make patients vulnerable to psychiatric disorders such as postpartum depression (ppd), anxiety, and stress disorders. women with postpartum psychiatric disorders have high mortality rates. the most common postpartum psychiatric disorder is ppd. ppd occurs any time in pregnancy or in the first four weeks after delivery. it may lead to complications such as emotional lability in the mother. this situation may also effect the child. postpartum depression (pd) has become the most frequent complication of childbirth. its prevalence has been estimated as 10%-15% and its formation is affected by several factors such as lack of social support, previous history of depression, and personal vulnerability. there are several studies about pd in the literature, some discuss about the relation of pain and pd, some discuss about the relation of epidural anesthesia and pd. however, there is no study that compares different anesthesia methods (general anesthesia vs spinal anesthesia) on development of postnatal depression after cesarean delivery. the aim of this study is to compare the different anesthesia methods (general anesthesia vs spinal anesthesia) on development of postnatal depression after cesarean delivery. the secondary aim is to decrease the ratio of postnatal depression after cesarean delivery.

Eligibility criteria:
inclusion criteria: * aged 21-50 years old * 36 gestational weeks or more, * american society of anesthesiologists' (asa) i and ii * able to communicate exclusion criteria: * history of bipolar or psychotic disorder * suicidal state * chronic pain syndrome * intraoperative complication * drug and/or alcohol abuse * who did not want to participate * emergency cases * unable to communicate in turkish

Keywords: anesthesia postnatal depression cesarean delivery
decompression coring versus conservative therapy in patients with avascular necrosis of the hip related to sickle cell disease

Conditions: Bone Avascular Necrosis; Sickle Cell Anemia

Summary: objectives: i. phase ii trial to determine surgical morbidity of decompression coring, including any adverse events in the perioperative period and the rate of secondary medical or surgical interventions. ii. collect preliminary data to determine if decompression coring results in a substantial improvement in pain and mobility compared to conservative therapy in patients with avascular necrosis of the hip related to sickle cell disease.

protocol outline: this is a randomized, multicenter study. patients are stratified according to stage of avascular necrosis (i vs ii vs iii). patients are randomized into one of two treatment arms. arm i: patients undergo a core biopsy and decompression of the hip followed by a standardized program of touch down or nonweight bearing with appropriate equipment and regular physical therapy for 6 weeks and then full weight bearing if tolerated. arm ii: patients undergo the standardized ambulation and physical therapy program as in arm i. they do not undergo any surgical procedure. for 1 week prior to the beginning of the standardized program and during the 6 weeks of touch down or nonweight bearing, all patients complete a weekly pain and medication diary. patients are followed at 3 months and 6 months, then every 6 months for 1.5 years, and then annually for up to 5 years.

Eligibility criteria:
inclusion criteria: * diagnosis of stage i, ii, or iii avascular necrosis (avn) by mri or plain film imaging that is related to sickle cell disease * clinically moderate to severe pain originating from the hip and/or limitation of movement of the affected hip * avn in the contralateral hip allowed, regardless of stage, if the primary hip is eligible if both hips eligible, most symptomatic hip enrolled exclusion criteria: * non-sickle cell arthropathies * concurrent chronic steroids * chronic transfusion therapy * alcoholism

Keywords: arthritis & connective tissue diseases avascular necrosis disease-related problem/condition genetic diseases and dysmorphic syndromes hematologic disorders pain rare disease sickle cell anemia
valerian for conscious sedation in patients submitted to impacted lower third molars surgery

Conditions: Dental Anxiety; Blood Pressure; Heart Rate

Summary: the aim of the present study was to evaluate the efficacy of valeriana officinalis l. 100 mg in single oral doses one hour preoperative as conscious sedation during the impacted lower third molar surgery.

evaluate the efficacy of valeriana officinalis l. (valerian) for control of anxiety during third molar surgery. study design: a single oral dose of either valerian (100 mg) or placebo was randomly administered one hour before each surgical procedure to 20 volunteers between 17 and 31 years of age. anxiety level was assessed through questionnaires, physiological parameters (blood pressure and heart rate) and the observation of signs.

Eligibility criteria:
inclusion criteria: * indication for bilateral extraction of asymptomatic impacted mandibular third molars in similar positions based on the pell \& gregory classification exclusion criteria: * use of any type of medication in the 15 days prior to the onset of the study; history of hypersensitivity to the drugs, substances or materials employed in the experiment; pregnancy or lactation
teneligliptin on the progressive left ventricular diastolic dysfunction with type 2 diabetes mellitus study

Conditions: Diabetes Mellitus, Type 2

Summary: this is the clinical trial designed to assess the cardiac diastolic function of long term treatment with teneligliptin compared to that without teneligliptin in patients with type 2 diabetes mellitus by two arms; one includes patients showing e/e' by echocardiography less than 8, the other includes patients showing e/e' by echocardiography more than 8.


Eligibility criteria:
inclusion criteria: * asians aged from 20 to 85 years old at baseline * patients with type 2 diabetes mellitus and including either a) or b) criteria. a) patients necessary to start the treatment using anti-diabetic agent(s) or to change the anti-diabetic agent(s). b) patients possible to change the anti-diabetic agent(s). * patients with left ventricular ejection fraction more than 40% * patients with written informed consent exclusion criteria: * patients with type 1 diabetes mellitus * patients with slowly progressive type 1 diabetes mellitus positive for pancreatic islets related autoimmune antibody as gad antibody or ia-2 antibody or ica antibody * patients with diabetes mellitus caused by evident genetic factors * patients with diabetes mellitus caused by secondary factors as endocrine disease or liver disease * patients with diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome * patients with any severe infectious diseases or planed any surgical treatments or suffered any severe traumas * patients with severe liver dysfunction * patients with hypophyseoprivic or adrenal insufficiency * patients under malnutrition or starved state or irregular caloric intake or calorie insufficiency or hyposthenia * patients judged to be unsuitable for the study as they are planning to exercise intensively * patients judged to be unsuitable for the study as they may drink excessively or abuse drugs * patients showing qt prolongation in the electrocardiogram * patients with any past histories of heart failure showing nyha classification grade more than 3 at baseline * patients with any past histories of acute coronary syndrome or coronary intervention or cardiac surgery developed within 6 months * patients with any surgical past histories of mitral valve replacement or mitral valve repair or severe calcification of mitral valve * patients already treated with teneligliptin * women with breast-feeding * pregnant women or patients who have possibilities of pregnancy * patients expected to live less than 3 years * patients with any past histories of drug hypersensitivity against teneligliptin * patients already involved in any other interventional clinical trials or planned to be involved * patients judged to be inappropriate for the study by the doctors in charge
randomized, double-blind, two arms, multicenter, phase iii study of berinert for treatment of ace induced angioedema

Conditions: Acute ACE-induced Angioedema

Summary: this trial is a randomized, double-blind, two arms, multicenter, phase iii study of berinert for treatment of ace induced angioedema. this study should show that berinert shortens the time to complete resolution of signs and symptoms of acute ace-induced angioedema of the upper airway tract compared to placebo when given on top of standard treatment. this study should also compare the time to onset of relief as defined by an at least one point reduction on the severity scale of ace-induced angioedema with berinert versus placebo.


Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study and ability to fulfil all study requirements * male or female patients aged \>=18 years * patients with ace induced angioedema (grade ii-iii) with imminent airway obstruction admitted to an emergency department * patient is being treated with acei * patient must have acute angioedema attack caused by acei * treatment should be administered within 10 hours after onset of the angioedema * patients with angioedema of the head and/or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx) * male participants and female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country * signed patient information consent form exclusion criteria: * diagnosis of angioedema of other genesis: e.g. hereditary angioedema, c1-inhibitor deficiency, allergic edema, anaphylaxis, insect bite, trauma, abscess, local inflammation, local tumour, post-operative or post-radiogenic edema, salivary gland disorders * participation in a clinical study in the past 30 days * patients with simultaneous itchiness of skin (acute urticaria) * patients with a history of angioedema before taking acei * history of hypersensitivity to any of the study drugs or medicine with a similar chemical structure. * pregnancy and/or breastfeeding * mental retardation of the patient with restriction of general judgment and awareness * history of drug abuse (including alcohol and alcoholic liver disorders) * potentially unreliable patients * patients who are not suitable for the study in the opinion of the investigator
cerebellar itbs in patients with disorders of consciousness

Conditions: Disorder of Consciousness; Vegetative State; Minimally Conscious State

Summary: previous studies showed the excitatory effect of cerebellar transcranial magnetic stimulation(tms) on motor cortex.investigator evaluate the effects of bilateral cerebellar tms on coma recovery scale-revised (crs-r) scores in patients with disorders of consciousness(doc) in a randomized, double-blinded, sham-controlled, crossover experimental design.

patients with disorders of consciousness(doc) resulting from severe brain injury greatly burden caregivers, health care facilities, and society. however, there is no definitively effective treatment for patients with doc. previous studies showed the excitatory effect of cerebellar transcranial magnetic stimulation(tms) on motor cortex through the dentato-rubro-thalamic tract. investigators aim to validate the effect of 5 consecutive sessions of intermittent theta-burst stimulation(itbs) of bilateral cerebellar on level of consciousness of patients in vegetative state(vs)/unresponsive awakening state(uws)or minimally conscious (mcs) state in a randomized, double-blinded, sham-controlled, crossover study. tms is a non-invasive and safe neural regulatory approach that is widely used in depression, schizophrenia, stroke, and parkinson's disease.

Eligibility criteria:
inclusion criteria: 1. vs/uws or mcs according to diagnostic criteria 2. age ≥18 years 3. written informed consent obtained exclusion criteria: 1. patients in coma 2. brain injury \<1week 3. presence of metallic hardware in close contact to the discharging coil（such as cochlear implants, or an internal pulse generator or medication pumps） 4. patients with high risks according to standard questionnaire to screen transcranial magnetic stimulation(tms) candidates

Keywords: tms cerebellar itbs doc mcs vs
positron emission tomography using 64cu-sar-bispsma in participants with high-risk prostate cancer prior to radical prostatectomy

Conditions: Prostate Cancer; Prostatic Neoplasms

Summary: the aim for this study is to assess the diagnostic performance of 64cu-sar-bispsma pet to detect regional nodal metastases.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * signed informed consent. * untreated, histologically confirmed adenocarcinoma of the prostate. * high-risk or greater pc defined by national comprehensive cancer network guidelines version 1.202327 (clinical stage ≥t3a, or grade group ≥4, or psa \>20 ng/ml). * patients electing to undergo rp with plnd. exclusion criteria: * administration of any high energy (\>300 kev) gamma-emitting radioisotope within 5 physical half-lives prior to day 1. * known or expected hypersensitivity to 64cu-sar-bispsma or any of its components. * patients with known predominant small cell or neuroendocrine pc.
prophylactic effect of nifedipine on further decline in renal function in patients undergoing open-heart surgery

Conditions: Kidney Failure, Chronic; Coronary Artery Disease

Summary: to compare renal function (51cr-edta clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients with impaired renal function after randomization to either nifedipine infusion at start of surgery and the following 24 hours or placebo (0.9% saline infusion). study hypothesis is that nifedipine has a prophylactic effect on decline in renal function.


Eligibility criteria:
inclusion criteria: 1. patients of either gender above 18 years of age. 2. patients with significant coronary stenosi(e)s (≥ 75% coronary artery lumen surface stenosi(e)s and / or aortic- or mitral valve vitriuim that are accepted for coronary artery bypass surgery and/or valve replacement surgery. 3. patients with impaired renal function, defined as increased serum- creatinine. men: ≥ 150 µmol/l and women: ≥130 µmol/l. exclusion criteria: 1. patients on maintenance hemodialysis 2. renal transplant patients 3. patients with ejection fraction ≤ 35% 4. patients with unstable angina pectoris

Keywords: preventive therapy calcium channel blockers kidney failure, chronic coronary artery bypass heart valve prosthesis implantation
to evaluate the effect of food on the pharmacokinetics (pk) of azd0328

Conditions: Healthy

Summary: the purpose of the study is to evaluate the effect of food on the pharmacokinetics of azd0328 in healthy male volunteers. azd0328 will be administered as a single oral dose (capsule) during two treatment periods, after food intake or during fasting condition.


Eligibility criteria:
inclusion criteria: * healthy male caucasian subjects. * clinically normal physical findings, laboratory values, vital signs and resting ecg as judged by the investigator. * signed informed consent form exclusion criteria: * history of clinically significant cardio or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder (including dyspepsia or gerd) or any other major disorder that may interfere with the study. * intake of another investigational drug or participation in another study which may interfere with the objectives of the study, within 12 weeks before the administration of the investigational product.

Keywords: azd0328 food effect
efficacy and safety of nebivolol (added to lisinopril or losartan) in hypertensive patients

Conditions: Hypertension

Summary: this study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.


Eligibility criteria:
inclusion criteria: * male or female, ambulatory outpatients 18-85 years old at screening * have a history of hypertension * qualifying laboratory results exclusion criteria: * severe hypertension, including chronic kidney disease * documented congestive heart failure * have clinically significant respiratory, liver, or heart disease * history of stroke, heart attack, or heart surgery in the last 6 months * have a history of hypersensitivity to nebivolol or other beta blockers.

Keywords: nebivolol bystolic ™ lisinopril losartan hypertension
nutritional psychological intervention and vomit-free management on survival and quality of life in advanced gastrointestinal tumors

Conditions: Digestive System Cancer; Digestive System Neoplasm

Summary: aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone


Eligibility criteria:
inclusion criteria: 1. age 18-75, male or female; 2. patients with advanced esophageal cancer, gastric cancer, liver cancer and colorectal cancer and other gastrointestinal tumors diagnosed by pathological histology or cytology; 3. expected survival ³ 8 weeks and able to receive long-term follow-up; 4. eastern cooperative oncology group(ecog)-performance status(ps) score of 0-2; 5. first-line treatment receiving standard oncology treatment and nutritional psychological intervention and vomit-free management group (study group); first-line treatment receiving only standard oncology treatment group (control group); 6. voluntarily signing an informed consent form. exclusion criteria: 1. other malignant tumors diagnosed within the previous 5 years, except for effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or effectively resected in situ cervical cancer or breast cancer; 2. history of psychiatric illness prior to the diagnosis of the tumor 3. patients who resist treatment 4. patients with poorly controlled severe heart disease, liver or kidney insufficiency, severe anemia, multiple lymph node enlargement, leukopenia, etc; 5. patients who are pregnant or have a pregnancy plan; 6. patients who, in the judgment of the investigator, are not suitable for inclusion in this study.
safety and efficacy of incb013739 plus metformin compared to metformin alone on glycemic control in type 2 diabetics

Conditions: Type 2 Diabetes

Summary: determine the effect of treatment with incb013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.


Eligibility criteria:
inclusion criteria: * established diagnosis of type 2 diabetes * stable dose of metformin for more than 8 weeks exclusion criteria: * subjects with addison's disease or cushing's syndrome * type 1 diabetes mellitus or secondary forms of diabetes * subjects with uncontrolled thyroid disease * history of renal impairment
the reliability assessment of emergency paramedics' fatigue using automated pupillometry

Conditions: Mental Fatigue; Emergency Paramedics' Fatigue

Summary: due to the limitations of current approaches to assess emergency paramedics' fatigue, a portable, quick, easy, and objective technique is required to be developed. the aim of the study was to investigate the reliability of automated pupillometry to assess mental fatigue based on a driver simulator.


Eligibility criteria:
inclusion criteria: * all participants held valid driving license of more than 2 years, with at least half of a year driving experience, had regular sleep pattern, normal or corrected to normal vision and no history of any psychiatric disorder. exclusion criteria: * none.

Keywords: pupillary light reflex (plr) automated quantitative pupillometry karolinska sleepiness scale (kss) heart rate variability (hrv) electroencephalography (eeg)
small incision technique versus upper blepharoplasty in upper eyelid medial pad fat removal

Conditions: Eyelid Diseases

Summary: medial upper eyelid pad of fat bulge is a common problem. small incision surgery could be a time-efficient, minimally invasive and scar formation procedure .

traditional upper eyelid blepharoplasty: an entire length upper eyelid crease followed by proper dissection are applied . identification and removal of medial pad of fat. small incision technique: 4 mm medial upper eyelid small incision followed by proper dissection to gain direct access to the medial fat pad removal

Eligibility criteria:
inclusion criteria: * upper eyelid medial pad of fat bulge exclusion criteria: other eyelid diseases and previous eyelid surgery

Keywords: upper eyelid pad fat blepharoplasty
symptom monitoring in hemodialysis

Conditions: End Stage Kidney Disease

Summary: the smarrt-hd trial is a cluster randomized trial of symptom monitoring with supported clinician follow-up using the smarrt-hd electronic patient reported outcome measure (eprom) system versus usual care. approximately 2400 patients at 30 geographically and racially diverse us hemodialysis clinics will be enrolled. the primary trial hypothesis is that regular symptom patient reported outcome measure (prom) administration with supported clinician follow-up in dialysis care will reduce suffering and improve outcomes by prompting treatment of unrecognized symptoms, and enhancing patient-care team communication. clinics randomized to the smarrt-hd group will adopt the use of smarrt-hd for 12 months. smarrt-hd is a symptom monitoring system that includes 1) tablet-based symptom reporting using a prom and 2) supported clinician follow-up consisting of symptom alerts, guidances for symptom management, and symptom tracking reports that are shared with patients. dialysis clinics randomized to usual care will not adopt smarrt-hd or any other trial-driven procedures. usual care clinics will monitor symptoms through clinical care interactions with participants and by administering a health related quality of life survey that includes questions about symptoms.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * treatment with hemodialysis at a participating dialysis clinic * english or spanish speaking exclusion criteria: * not willing to report their symptoms using the smarrt-hd platform * not willing to share clinically acquired data with the research team * underlying condition such as dementia that is anticipated to prevent comprehension of the trial information document (fact sheet) * incarceration

Keywords: end stage kidney disease kidney hemodialysis dialysis symptom monitoring electronic patient-reported outcome measure (eprom)